Navigation Links
Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
Date:7/1/2011

NUEDEXTA® is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias. The primary outcome measure, laughing and crying episodes, was significantly lower in the NUEDEXTA arm compared to placebo. The secondary outcome measure, the Center for Neurologic Studies Lability Scale (CNS-LS), demonstrated a significantly greater mean decrease in CNS-LS score from baseline for the NUEDEXTA arm compared to placebo.

NUEDEXTA Important Safety Information

NUEDEXTA can interact with other medications causing significant changes in blood levels of those medications and/or NUEDEXTA. NUEDEXTA is contraindicated in patients receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine and pimozide) and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine. NUEDEXTA is contraindica
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... SAN DIEGO and WALTHAM, Mass., July 29, ... LLP is investigating whether certain officers ... breached their fiduciary duties to shareholders.  AMAG Pharmaceuticals ... on maternal health, anemia, and cancer supportive care.  ... to reduce the risk of preterm birth in ...
(Date:7/29/2015)... July 29, 2015  Cryoport, Inc. (NASDAQ: ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, announced today that the ... stock and warrants (the "Units") under a registered public ...
(Date:7/29/2015)... FRANCISCO , July 29, 2015   KaloBios ... antibody company focused on developing innovative therapies to benefit ... focus on oncology, announced today that the U.S. Food ... new drug (IND) application for KB003, an anti-GM-CSF monoclonal ... and that the IND is now active. ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of AMAG Pharmaceuticals, Inc. (AMAG) on Behalf of Shareholders 2Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 2KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 4KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 5
... , PRINCETON, N.J., Nov. 9 Pharmasset, Inc. (Nasdaq: ... Lazard Capital Markets Healthcare Conference. The conference will be held ... 17-19, 2009). , Schaefer Price, Pharmasset,s President and Chief Executive ... November 18, 2009 at 3:45 PM (ET). , To access ...
... 9 Par Pharmaceutical Companies, Inc. (NYSE: PRX ... date and increased the purchase price of its previously ... is offering to purchase, for cash, up to $65,000,000 ... its outstanding 2.875% Senior Subordinated Convertible Notes due 2010. ...
Cached Medicine Technology:Pharmasset to Present at Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at Lazard Capital Markets Healthcare Conference 3Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 2Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 3
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... success of musical artists to crowd-funding campaigns that give small businesses financial support, ... health solutions company and innovator in employee health management programs, unveiled today a ...
(Date:7/29/2015)... ... July 29, 2015 , ... Gender minority people ... 2012, Massachusetts law has provided legal protections against discrimination on the basis of ... not protect against discrimination based on gender identity in places open to the ...
(Date:7/29/2015)... Washington, DC (PRWEB) , ... July 29, 2015 , ... ... a company rebrand, changing its name to Rock the Reformer ® by Potomac Pilates. ... website - http://www.RockTheReformer.com . Rock the Reformer ® by Potomac Pilates will continue ...
(Date:7/29/2015)... ... July 29, 2015 , ... More than 28,000 students ... of children living with autism will converge upon Penn State to share the ... The National Autism Conference will be held Aug. 3-6 at the Penn Stater ...
(Date:7/29/2015)... ... July 29, 2015 , ... The NCCA re-accredited the ... expiring November 30, 2019, during its recent meeting. , The Commission received renewal ... program’s compliance with the NCCA’s Standards for the Accreditation of Certification Programs. ...
Breaking Medicine News(10 mins):Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 2Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 3Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 4Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 2Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 3Health News:Same Great Pilates Studio, New Brand - Rock the Reformer 2Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3
... , , BASKING RIDGE, N.J., Sept. ... the development of antithrombotic therapeutic aptamers with active control ... the first patient in a Phase 2b, randomized, partially-blinded, ... the REG1 anticoagulation system (REG1) was achieved. REG1 ...
... TARRYTOWN, N.Y., Sept. 9 Bayer Diabetes Care today ... glucose meters -- Pink and Purple. , , ... to use(1) features as the original silver BREEZE2 meter, such as ... so users do not have to handle individual strips every time ...
... to develop PAD if they had constellation of other ... News) -- Women with metabolic syndrome are at high ... dramatically raises the risk of heart disease and stroke. ... taking part in the Women,s Health Study, researchers identified ...
... ... Staffing and Scheduling Earned the Highest Score Based on Direct Product Evaluations and In-depth, ... ... 9, 2009 -- Today at the Nursing Management Congress2009, RES-Q® Healthcare Systems announced that ...
... , WALTHAM, Mass., Sept. 9 ... research and advisory firms focusing on pharmaceutical and healthcare issues, ... messages among the ten surveyed osteoporosis brands likely as a ... commonly recalled that Sally Field promoted the brand or that ...
... , , ATLANTA, ... may have ended, but financial incentives for improving health and appearance ... Surgical Associates, "Cash for Crow,s Feet" program offers a ... at half the typical cost, said Dr. David R. Fern, FACS. ...
Cached Medicine News:Health News:Regado Biosciences Announces First Patient Enrolled in RADAR (Phase 2b) Study of REG1 Anticoagulation System 2Health News:Regado Biosciences Announces First Patient Enrolled in RADAR (Phase 2b) Study of REG1 Anticoagulation System 3Health News:Bayer's BREEZE(R)2 Meter Available in Two New Vibrant Colors for a Limited Time 2Health News:Metabolic Syndrome May Raise Risk of Peripheral Artery Disease 2Health News:RES-Q Labor Resource Management Ranked as the Top Staff Scheduling System Solution in KLAS 2009 Special Report 2Health News:Both Patients and Physicians Most Frequently Recall Roche's Boniva Messages and Link Them to the Sally Field Osteoporosis Campaign 2Health News:Both Patients and Physicians Most Frequently Recall Roche's Boniva Messages and Link Them to the Sally Field Osteoporosis Campaign 3Health News:'Cash For Crow's Feet' Program Offers Effective - and Affordable - Laser Skin Treatments 2
BD Beaver Cataract blade, 30.0 mm long x 2.2 mm wide, designed for ICCE and ECCE procedures, designed for ICCE and ECCE, sterile....
BD Beaver DeBakey blade, 5 mm cutting width, sterile....
... standard trial frames. They are made of optical quality ... box. There are two sets available providing a full ... is that a patient can wear the prism with ... the patient to adapt to the use of the ...
Developed for reconstructive plastic surgery with E-Type coupling. Order blades by size from 12 mm, 25 mm, 50 mm or 75 mm depending on your specific case requirements. Blades come in packs of 10....
Medicine Products: